Category: 23256-42-0

On October 11, 2006, Wang, Lianmin; Zhang, Xinglong; Hua, Yunfang published a patent.Category: pyrimidines The title of the patent was Manufacture of veterinary amikacin sulfate compound injection containing trimethoprim. And the patent contained the following:

The title injection is manufactured by: (1) dissolving trimethoprim lactate into injection water, and adding propanediol, (2) dissolving sodium metabisulfite into injection water, (3) dissolving amikacin sulfate in injection water, and (4) mixing solutions obtained from step 1, 2, and 3, adjusting pH to 4.0-5.0, prefiltering, microfiltering, and sterilizing to obtain the final product. This injection can be used to synthesize abnormal proteins from bacteria to inhibit proteins from releasing, and enlarge cell membrane permeability of bacteria to inhibit proliferation of bacteria. This injection has reinforced antibacterial effect through synergistic effect of trimethoprim and amikacin sulfate. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to veterinary amikacin sulfate injection trimethoprim, Pharmaceuticals: Formulation and Compounding and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 1982, Takagishi, Yasushi; Ohsuga, Kiichiro; Ohama, Sadao published a patent.Related Products of 23256-42-0 The title of the patent was Suppositories containing sulfamethoxazole and trimethoprim. And the patent contained the following:

A pharmaceutical or veterinary composition for coelomic administration, especially a suppository, contains sulfamethoxazole (I) [723-46-6] and trimethoprim (II) [738-70-5] (1:1-10:1) or their salts and a small amount of a phospholipid to prevent solidification during mixing the above ingredients and to avoid the delayed disintegration. An organic acid may be added to increase the absorption of II. Thus, a suppository containing I 20, II 4, soybean lecithin 2, and Witepsol 74 parts had a disintegration time of 13 min after storage at room temperature for 3 mo, whereas the control without the lecithin did not decompose even after 60 min. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to sulfamethoxazole trimethoprim suppository lecithin, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 20, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Compound sulfaquinoxaline sodium composition for treating coccidiosis of young rabbits. And the patent contained the following:

The title composition contains toltrazuril 0.5-1, sulfaquinoxaline sodium 4-6, trimethoprim lactate 0.8-1.2, sodium citrate 15-25, sodium CM-cellulose 1.5-2.5, sodium sulfite 0.2-0.5, EDTA-2Na 0.2-0.5 weight part, and distilled water. The preparation method of the composition comprises: taking all materials, grinding, screening via 80 mesh sieve; taking sodium sulfite and EDTA-2Na, dissolving in distilled water sequentially, stirring uniformly, adding sodium citrate, mixing for 5-10min; adding toltrazuril, sulfaquinoxaline sodium and trimethoprim lactate, mixing for 5-10min, adding sodium CM-cellulose, stirring uniformly, and filtering. The composition has simple preparation method, and obvious curative effect on coccidiosis of young rabbits. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to sulfaquinoxaline sodium composition coccidiosis, Pharmaceuticals: Formulation and Compounding and other aspects.Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 9, 2014, Liu, Changdou published a patent.Computed Properties of 23256-42-0 The title of the patent was Compound colinflosaxin soluble powder for preventing and treating poultry colibacillosis. And the patent contained the following:

The invention discloses a compound colinflosaxin soluble powder for preventing and treating poultry colibacillosis, wherein the solubility powder is made of following components by weight percent: colinflosaxin 4-10%, florfenicol sodium succinate 5-10%, neomycin sulfate 3-10%, trimethoprim lactate 3-8%, and pharmaceutically acceptable adjuvants in balance. The invention importantly considers drug resistance properties of Escherichia coli, will not miss any one pathogenic microorganism, and comprehensively considers the reasons of harm to body, has broad spectrum, is effective to Escherichia coli, has strong antibacterial activity, adopts novel antibacterial drugs, such as colinflosaxin, florfenicol sodium succinate, by combining both of them for use, its antibacterial activity compared with conventional antibacterial drugs is greatly increased, and can effectively control secondary infection. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Computed Properties of 23256-42-0

The Article related to colinflosaxin powder poultry colibacillosis, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 9, 2011, Xu, Kefu published a patent.Application of 23256-42-0 The title of the patent was Medical composition for treating bacterial infection in digestive tract of poultry and its formulation. And the patent contained the following:

The title medical composition is composed of florfenicol 5-15, sulfamonomethoxine sodium 5-15, taurine 5-15, trimethoprim lactate 1-3, NaCl 5, KCl 5%, and addnl. anhydrous glucose. The medical composition is prepared by grinding the raw materials except for anhydrous glucose through 5# sieve resp., mixing uniformly, and adding anhydrous glucose. The medical composition may be used to prepare the medical preparations treating bacterial infection in digestive tract of poultry, with good synergistic effect, no side effect and definite and stable therapeutic effect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to bacterial infection digestive tract poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about bos taurus.Related Products of 23256-42-0 The title of the patent was Method for preparing veterinary tilmicosin premix powder drug. And the patent contained the following:

The invention belongs to the field of veterinary medicine technol. The title method comprises the following steps: crushing and sieving tilmicosin, trimethoprim lactate and anhydrous glucose, resp., weighing two raw materials of tilmicosin and trimethoprim lactate, adding anhydrous glucose, premixing, and adding anhydrous glucose, and fully mixing. The combination of the tilmicosin and the synergist is adopted to enhance the treatment effect of the integral powder, and can be used for treating infectious pleuropneumonia, plague, asthma and the like of pigs or cattle. After oral administration, the medicine is fast to absorb, and is characterized by strong tissue penetrating power, high concentration in lung and long effective blood concentration maintaining time. The preparation is stable, the preparation process is simple, and the use is convenient. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to veterinary tilmicosin premix powder drug, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about bos taurus.Product Details of 23256-42-0 The title of the patent was Tilmicosin premix powder veterinary drug. And the patent contained the following:

The invention belongs to the tech. field of veterinary medicine. The title powder consists of tilmicosin, trimethoprim lactate, and anhydrous glucose. The combination of tilmicosin and synergist is adopted to enhance the treatment effect of the integral powder, and can be used for treating infectious pleuropneumonia, plague, lung disease and the like of pigs or cattle. After oral administration, the medicine is fast to absorb, and is characterized by strong tissue penetrating power, high concentration in lung and long effective blood concentration maintaining time. The medicine is stable, the preparation process is simple, and the use is convenient. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to tilmicosin premix powder veterinary drug, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Zheng, Xing-xing; Ouyang, Wu-qing published an article in 2016, the title of the article was Preparation of erythromycin nanoemulsion and determination of its bacteriostatic activity in vitro.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate And the article contains the following content:

[Objective] To prepare erythromycin nanoemulsion, and to research its bacteriostatic activity in vitro. [Method] The preparation of the erythromycin nanoemulsion was optimized by studying the pseudoternary phase diagram. Broth dilution method was used to determine the MIC and MBC of erythromycin nanoemulsion on enteropathogenic Escherichia coli, Staphylococcus aureus, Pneumococcus and Proteus. [Result] The mass fraction of the components in erythromycin nanoemulsion included 2.8% erythromycin, 0.6% trimethoprim lactate, 35.2% EL-40, 7.5% cinnamaldehyde, and 53.9% distilled water. The susceptibility test revealed that the MIC of erythromycin nanoemulsion on enteropathogenic E. coli, S. aureus, Pneumococcus and proteus was 4, 1, 2 and 4μg/mL, resp. Their antibacterial effects significantly was better than other drugs. [Conclusion] The erythromycin nanoemulsion is successfully prepared, and its antibacterial effect in vitro is remarkable. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to erythromycin nanoemulsion bacteriostatic, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 22, 2019, Shen, Lianbing; Chen, Yongqiang; Zhou, Yiping; Zhang, Anlian published a patent.Product Details of 23256-42-0 The title of the patent was Easily soluble compound sulfachloropyridazine sodium powder. And the patent contained the following:

The invention discloses a soluble compound sulfachloropyridazine sodium powder with high water solubility and good quality. The compound sulfachloropyridazine sodium powder comprises the following raw materials: sulfachloropyridazine sodium, trimethoprim and D-sucrose. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to solubility sulfachloropyridazine sodium, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 26, 2016, Zhang, Ronghao; Shao, Zhigang; Hou, Qiang published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Medicine for treating salpingitis of laying poultry. And the patent contained the following:

The present invention discloses a medicine for treating salpingitis of laying poultry, which comprises raw materials by weight part: Scutellaria baicalensis 6-8, Paeonia suffruticosa 5-10, Panax japonicus 3-5, Agrimonia pilosa 5-7, Corydalis yanhusuo 7-8, Radix Paeoniae Rubra 4-6, Herba Epimedii 6-8, Cnidium monnieri 2-4, Hordeum vulgare 6-10, medicated leaven 8-10, Melia toosendan 2-4, Euryale ferox 5-8, Luffa cylindrica 12-16, Cuscuta chinensis 6-10, Manis pentadactyla 2-4, Clausena excavata 4-6, Solidago decurens 6-8, Trollius macropetalus 1-3, amoxicillin 80-100, ciprofloxacin 80-100, lactic acid TMP 20-25, anhydrous sodium sulfate 650-700, and glucose powder 120-150. The invention has scientific medicines compatibility, simple administration in combination with feed, lower cost, no drug residue and toxic side effect. Combination of all medicines has effects such as effectively clearing heat and detoxicating, replenishing qi to invigorate the spleen, promoting blood circulation and hemostasis, and significant therapeutic effect to salpingitis of oviparous poultries, which effectively improves egg laying rate of laying birds, greatly increases the economic benefit of farmer. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to medicine salpingitis laying poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia